These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

162 related items for PubMed ID: 15526836

  • 1. Rituximab maintenance stretches progression-free survival in patients with indolent NHL.
    Oncology (Williston Park); 2004 Sep; 18(10):1316. PubMed ID: 15526836
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Rituximab and its role as maintenance therapy in non-Hodgkin lymphoma.
    Collins-Burow B, Santos ES.
    Expert Rev Anticancer Ther; 2007 Mar; 7(3):257-73. PubMed ID: 17338647
    [Abstract] [Full Text] [Related]

  • 5. Maintenance therapy for low-grade lymphomas: has the time come?
    Cartron G, Solal-Céligny P.
    Curr Opin Oncol; 2007 Sep; 19(5):425-32. PubMed ID: 17762565
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. [A three-year experience with use of mabthera (rituximab) in treatment of indolent non-Hodgkin's disease refractory to standard chemotherapy].
    Korolenko VO, Gershanovich ML, Tikhonova VV.
    Vopr Onkol; 2004 Sep; 50(4):421-5. PubMed ID: 15605764
    [No Abstract] [Full Text] [Related]

  • 8. Maximizing therapeutic benefit of rituximab: maintenance therapy versus re-treatment at progression in patients with indolent non-Hodgkin's lymphoma--a randomized phase II trial of the Minnie Pearl Cancer Research Network.
    Hainsworth JD, Litchy S, Shaffer DW, Lackey VL, Grimaldi M, Greco FA.
    J Clin Oncol; 2005 Feb 20; 23(6):1088-95. PubMed ID: 15657401
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Sixth biannual report of the Cochrane Haematological Malignancies Group--focus on non-Hodgkin lymphoma.
    Weingart O, Rehan FA, Schulz H, Naumann F, Knauel I, Bohlius CB, Engert A.
    J Natl Cancer Inst; 2007 Sep 05; 99(17):E1. PubMed ID: 17728205
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. [Efficacy of rituximab-containing salvage regimens on relapsed or refractory B-cell non-Hodgkin's lymphoma].
    Huang HQ, Bu Q, Xia ZJ, Lin XB, Wang FH, Li YH, Peng YL, Pan ZH, Wang SS, Lin TY, Jiang WQ, Guan ZZ.
    Ai Zheng; 2006 Apr 05; 25(4):486-9. PubMed ID: 16613686
    [Abstract] [Full Text] [Related]

  • 14. New treatment approaches to indolent non-Hodgkin's lymphoma.
    Seymour JF.
    Semin Oncol; 2004 Feb 05; 31(1 Suppl 2):27-32. PubMed ID: 15042532
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. ECOG 4402: randomized phase III-trial comparing two different rituximab dosing regimens for patients with low tumor burden indolent non-Hodgkin's lymphoma.
    Williams ME.
    Curr Hematol Rep; 2004 Nov 05; 3(6):395-6. PubMed ID: 15496271
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.